New Business Opportunities in Bio/Pharma,
Medical Devices & Diagnostics

January 2017

Welcome to the January 2017 issue of PharmSource PERISCOPE

This monthly e-newsletter provides valuable insight to sales and marketing professionals who sell goods and services to bio/pharma, medical device or diagnostic companies. It helps you recognize new business opportunities and overcome sales obstacles.

Enjoy the January issue, and Happy New Year!

The PharmSource Team


PharmSource Lead Sheet
Summary of Global Clinical Pipeline Activity

Lead Type December 2016 CY 2016
Early Development 88 1384
Late Development 93 1397
Biologic 94 1244
Small Molecule 207 3027
Parenteral 92 1340
Oral 85 1176
New Financings 70 924
Total Drug Leads 376 4477
Total Device &
Diagnostic Leads
137 1681

*Total leads include acquisitions/alliances, company acquisition/alliances and events.


Pipeline Tip

Adynxx plans to initiate a Phase II trial with AYX1 for the prevention of chronic pain after major surgery:

  • Therapeutic Area: Analgesic – Non-narcotic
  • Dosage Form: Parenteral
  • API: Nucleic acid – DNA

Get deeper information about the likely upcoming needs of Adynxx, its pipeline, contacts and more in the PharmSource Lead Sheet. If you’re not yet a subscriber, click here to learn more.

CRISPR: Gene Therapy 2.0

by Mahdia Hashimy, Research Analyst

It looks like 2017 will be an exciting year for the Biotech industry. One development that has caught much attention is the new generation of gene therapy, the CRISPR-Cas9 genome editing tool that with cautious optimism is expected to start a new wave of faster, more accurate treatment for monogenetic diseases through DNA modification.

With the CRISPR-Cas9, (Clustered Regularly Interspaced Short Palindromic Repeats) editing tool, scientists are able to accurately alter a DNA sequence, removing and replacing faulty DNA, and have the potential to treat a range of genetic medical conditions. With around 5,000 inherited disorders caused by… read on

Follow the Money to

Bio/Pharmaceutical Opportunities

Spotlight on Clearside Biomedical, Inc.

Clearside Biomedical is a U.S. public bio/pharmaceutical company that develops and commercializes therapeutic products using an ocular microinjection platform to target the individual compartments of the eye. They plan to raise $36 million in a secondary public offering.

What new business opportunities are most likely to surface from this? We know they plan to use the proceeds to continue early-stage R&D and to complete… read on

Follow the Money to

Medical Device & Diagnostic Opportunities

Spotlight on Femasys, Inc.

Femasys is a U.S. private company that develops and manufactures medical devices for the treatment of infertility and cervical cancer. They raised $40 million in a completion of a Series C venture capital investment.

What new business opportunities are most likely to surface from this? We know they plan to use the proceeds to support the pivotal trial of the FemBloc… read on

How much longer is the boom in the CDMO and CRO business likely to continue?

PharmSource’s just-released trend report, Follow the Money: The Outlook for Outsourced Spending on Early Development Services, examines the link between external funding sources and early drug development, and addresses the following:

1. How close is the link between early development activity and the external funding environment?

2. What happens to R&D spending when an emerging bio/pharma company gets financing? What happens to other spending categories?

3. What is the cost of getting a candidate into Phase 1 and Phase 2?


PharmSource Lead Sheet

The PharmSource Lead Sheet is the industry’s definitive source for identifying targeted new business opportunities in bio/pharmaceutical companies around the world. Our dedicated research team knows how and where to find fresh, targeted leads, and we have the contact information you need to start the sales process.

Don’t be the last to learn about the latest business development opportunities. If you’re not already using the Lead Sheet, contact us today to schedule a complimentary test-drive.

See for yourself how this resource can be a vital tool for building your brand and growing your market share.

To request a test-drive today, contact Nathaniel Celentano at / 1-703-383-4903, ext. 112 (ET USA).